STCube announced on the 10th that patient dosing for phase 1b of the investigator-initiated phase 1b/2 clinical trial of ‘Nelmastobart’ for colorectal cancer has been completed. Since improvement ...

Stcube (052020) has delivered a 17% change over the past year, with a 52-week range between 5,500 and 9,890. What Is the Average Daily Trading Volume of Stcube (052020)? The average daily trading ...

STCube presented a roadmap for next-generation non-small cell lung cancer (NSCLC) treatment strategies at the World Conference on Lung Cancer (WCLC 2025). On September 15, STCube announced its plans ...

STCube announced on the 21st that it has received approval from the Ministry of Food and Drug Safety for the investigational new drug application (IND) for the immune anticancer candidate nelmastovat ...

Samsung Biologics announced Wednesday that it has signed a partnership deal with STCube for the development and manufacturing of STT-003, an anti-cancer immunotherapy candidate. STT-003, developed by ...

"Stage 4 colorectal cancer is a malignant condition that spreads to other organs such as lymph nodes, liver, and lungs, which most existing treatment methods fail to address. The survival period ...

Samsung BioLogics said Tuesday that it has signed a contract development service agreement for STCube’s anticancer drug candidate. Under the agreement, Samsung BioLogics will lead cell line ...

SONGDO, South Korea, March 2, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and STCube announced a strategic development and manufacturing service agreement for STT-003 antibody, an anti-cancer ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

SONGDO, South Korea, July 11, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has further expanded its partnership with STCube through an additional development and manufacturing service agreement ...